Testosterone enanthate
Long-acting testosterone ester with a half-life close to cypionate. Largely interchangeable for scheduling.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Testosterone enanthate
Long-acting testosterone ester with a half-life close to cypionate. Largely interchangeable for scheduling.
Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.
Regulatory statement in source: FDA-approved.
Testosterone enanthate injection is approved by the US FDA as testosterone replacement therapy in adult males with conditions linked to low or absent natural testosterone. The label states that safety and effectiveness were not established in men with age-related hypogonadism or in males under 18. In July 2025 the label removed its boxed warning about blood pressure increases and its cardiovascular-risk warning, while still warning that testosterone can raise blood pressure. An FDA presentation on testosterone replacement describes the same class indication. The evidence here is regulator-approved product labelling, not a new trial.
Benefits reported in the imported source
- Testosterone replacement in adult males with low or absent natural testosterone.
Risks and limits
- Safety and effectiveness were not established in age-related low testosterone or in males under 18.
- The label still warns that testosterone can raise blood pressure.
- In July 2025 the boxed blood-pressure warning and the cardiovascular-risk warning were removed.
Source bottom line: Testosterone enanthate is FDA-approved replacement for men with low testosterone, but not proven for age-related decline.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
adult males with primary or hypogonadotropic hypogonadism, per the US label for Xyosted testosterone enanthate injection
- Reported regimen
- 75 mg injected subcutaneously in the abdomen once a week, adjusted on trough testosterone measured 7 days after the most recent dose
- Duration
- ongoing, per the label
- Reported outcome
- The label states safety and efficacy were not established in men with age-related hypogonadism or in males under 18.
- Source
- FDA label for Testosterone Enanthate Injection
Claim provenance
evidence.json#/catalog:hormone:testosterone-enanthate/protocols/0
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Testosterone Enanthate Cycle Guide
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: Community users report beginner testosterone enanthate cycles at 500 mg per week, with advanced protocols using 500–750 mg per week combined with additional compounds, and cutting cycles as low as 250 mg every other day.
Testosterone Enanthate Cycle Guide (availability check 2026-10-15: source not retrieved; HTTP 403)
Pharmacokinetic context
Historical half-life estimate: 108–132 hours. FDA label Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- FDA label for Testosterone Enanthate Injection
- Testosterone Replacement Therapy: Current Regulatory Landscape
- DailyMed: testosterone enanthate
Snapshot provenance
Source ID: catalog:hormone:testosterone-enanthate. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.